Put our insights to work for your brand by accessing our newest solution, HCP Message Monitor. https://ow.ly/mTfH50SAK1p
MMIT (Managed Markets Insight & Technology)
Information Services
Yardley, Pennsylvania 46,533 followers
About us
For nearly two decades MMIT has been solely focused on solving the “what and why” of drug coverage, and has been a trusted, go-to-market partner to pharma companies, payers and providers. We believe that patients who need lifesaving treatments shouldn’t face delays because accessing drugs can be confusing. As the leading provider of market access data, analytics and insights, our expert teams of clinicians, data specialists and market researchers provide clarity and confidence so that our clients can make better decisions. Divisions of MMIT include AIS Health, creator of the Directory of Health Plans and leading healthcare publications; Zitter Health Insights, a preeminent provider of market access insights and solutions for specialty drugs; RJ Health, the market leader in pricing and coding solutions for infusion drugs covered under the medical benefit; and The Dedham Group, a U.S. market access oncology and specialty therapeutics consultancy offering research, data analytics and strategy formulation services to the life sciences industry.
- Website
-
http://www.mmitnetwork.com
External link for MMIT (Managed Markets Insight & Technology)
- Industry
- Information Services
- Company size
- 201-500 employees
- Headquarters
- Yardley, Pennsylvania
- Type
- Privately Held
- Specialties
- Formulary, Policy & Restriction Transparency, Mobile Formulary Search Application, Launch Commercialization Guidance, and Formulary Management & Publishing
Locations
Employees at MMIT (Managed Markets Insight & Technology)
Updates
-
Evidence-based physician education plays an important role in market access for any new drug—whether it's the first therapy in an indication or the fourth. https://ow.ly/fZIf50SUX2K In BioPharma Dive, Norstella's Dr. Shrinal Patel and MMIT's Carolyn Zele explain why disease state education is critical. #MarketAccess #Pharma #Physicians #PhysicianEducation
-
-
In the latest issue of AIS Health's Radar on Specialty Pharmacy, participants in CMS's Enhancing Oncology Model discuss the benefits and challenges of the patient-centered care model. Subscribe and save to any AIS Health publication this month with discount code SAVE10%. #pipeline2patient Norstella https://hubs.ly/Q02KWPNL0
-
In the past few years, it’s become more challenging for pharmaceutical companies to promote their products directly to healthcare providers. So, how can manufacturers best promote their brands in this evolving environment? The short answer is that brand teams are getting creative out there. MMIT’s Jay Shah outlines four trends we’re seeing in successful physician engagement campaigns: https://ow.ly/rx6r50Rvg3J. #Pharma #HCPs #PharmaceuticalReps #PhysicianOutreach #HealthcareTrends
-
Pharma companies can help patients access biomarker testing by providing resources on patient identification, available vendors, proof of eligibility, and ordering instructions. MMIT and The Dedham Group share tips for oncology manufacturers in Drug Channels: https://ow.ly/XFNh50Sphyc. #Pharma #PharmaManufacturers #MarketAccess #Oncology
Solving Access Barriers in Biomarker Testing: 5 Tips for Manufacturers | Drug Channels
drugchannels.net
-
For a successful drug launch, it's crucial for #pharma companies to start #MarketAccess planning 12-18 months prior to FDA approval. Our insightful ebook will walk you through enhancing your drug's formulary position, payer coverage and product messaging. https://ow.ly/nVKl50RsZJJ
-
More than half of #pharma companies are starting #MarketAccess planning by Phase II or III, and 33% are beginning even earlier, in Phase I. https://ow.ly/VJgo50Su4XA Learn how pharma is coping with increased financial pressures in this 2024 State of Patient Access Survey report.
-
-
New in this week's Health Plan Weekly: Can CVS's Lynch right the Aetna ship? Also, PBM lawsuits drop like dominoes after FTC report, insurtechs' narrowed focus paid off in 2Q, and experts consider policy solutions and plan innovations to the long-term care crisis. https://hubs.ly/Q02KN1800
Health Plan Weekly
mmitnetwork.com
-
MMIT's RWD data and HCP Targeting Report can help evaluate your therapy's full market potential, from the number of patients diagnosed to the high-value HCPs in the space. Learn more: https://ow.ly/46QH50SJER8
-
-
New in this week's Radar on Drug Benefits: GOP lawmakers demand examination of Part D stabilization demo, Big Three PBMs get defensive on 2Q earnings calls, and industry leaders urge payers to get more involved in real-world evidence generation. #realworldevidence #realworlddata #pipeline2patient #MedicarePartD https://hubs.ly/Q02Kz2Gb0
Radar on Drug Benefits
mmitnetwork.com